trym tirzepatide Oral Trym Health is lying &

Based on the analysis, tirzepatide is expected to receive FDA approval for obesity by the end of 2023, and analysts predict that its sales could surpass those of Wegovy, provided that Lilly can continue to build on the potentially superior efficacy of tirzepatide

In a statement, Scott Brunner, CEO of the Alliance for Pharmacy Compounding, questioned whether the FDA's resolution of the shortage had taken into account demand for the compounded drug and "the number of patients wholl need to be transitioned from a compounded version to a FDA-approved version. "Thats likely hundreds of thousands of patients," Brunner said

I am eating healthier and very satisfied with smaller portions

maintenance dose 2.4 mg Oral Wegovy pill: Once daily tablet

Across cardiometabolic cohorts, tirzepatide users showed fewer new macro-albuminuria cases and steadier perfusion patterns